News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
870,468 Results
Type
Article (88011)
Company Profile (825)
Press Release (781613)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (233285)
Career Advice (4147)
Deals (39884)
Drug Delivery (151)
Drug Development (91429)
Employer Resources (205)
FDA (18399)
Job Trends (17428)
News (397960)
Policy (39972)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3012)
Academic (2)
Accelerated approval (34)
Adcomms (36)
Allergies (148)
Alliances (56982)
ALS (181)
Alzheimer's disease (1795)
Antibody-drug conjugate (ADC) (348)
Approvals (18576)
Artificial intelligence (632)
Autoimmune disease (166)
Automation (38)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (203)
Biotechnology (490)
Bladder cancer (163)
Brain cancer (65)
Breast cancer (668)
Cancer (5064)
Cardiovascular disease (448)
Career advice (3570)
Career pathing (41)
CAR-T (305)
CDC (59)
Celiac Disease (2)
Cell therapy (833)
Cervical cancer (37)
Clinical research (77061)
Collaboration (1833)
Company closure (5)
Compensation (1167)
Complete response letters (73)
COVID-19 (2994)
CRISPR (99)
C-suite (873)
Cystic fibrosis (154)
Data (6295)
Decentralized trials (2)
Denatured (72)
Depression (151)
Diabetes (535)
Diagnostics (7237)
Digital health (48)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (304)
Drug pricing (225)
Drug shortages (36)
Duchenne muscular dystrophy (239)
Earnings (100176)
Editorial (64)
Employer branding (25)
Employer resources (173)
Events (135107)
Executive appointments (1033)
FDA (21600)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1560)
Gene editing (216)
Generative AI (67)
Gene therapy (676)
GLP-1 (1136)
Government (5446)
Grass and pollen (8)
Guidances (386)
Healthcare (20948)
HIV (63)
Huntington's disease (49)
IgA nephropathy (86)
Immunology and inflammation (292)
Immuno-oncology (60)
Indications (100)
Infectious disease (3282)
Inflammatory bowel disease (206)
Inflation Reduction Act (17)
Influenza (120)
Intellectual property (249)
Interviews (816)
IPO (17958)
IRA (60)
Job creations (5200)
Job search strategy (2866)
JPM (70)
Kidney cancer (17)
Labor market (93)
Layoffs (660)
Leadership (40)
Legal (10160)
Liver cancer (99)
Longevity (16)
Lung cancer (681)
Lymphoma (380)
Machine learning (45)
Management (66)
Manufacturing (860)
MASH (175)
Medical device (15035)
Medtech (15089)
Mergers & acquisitions (22995)
Metabolic disorders (1410)
Multiple sclerosis (164)
NASH (23)
Neurodegenerative disease (356)
Neuropsychiatric disorders (101)
Neuroscience (3124)
Neurotech (1)
NextGen: Class of 2026 (7708)
Non-profit (5112)
Now hiring (66)
Obesity (684)
Opinion (336)
Ovarian cancer (167)
Pain (214)
Pancreatic cancer (231)
Parkinson's disease (301)
Partnered (39)
Patents (512)
Patient recruitment (489)
Peanut (60)
People (66932)
Pharmaceutical (145)
Pharmacy benefit managers (33)
Phase 1 (23810)
Phase 2 (33439)
Phase 3 (25197)
Pipeline (5148)
Policy (339)
Postmarket research (3554)
Preclinical (10694)
Press Release (72)
Prostate cancer (249)
Psychedelics (56)
Radiopharmaceuticals (301)
Rare diseases (915)
Real estate (7440)
Recruiting (80)
Regulatory (29056)
Reports (67)
Research institute (2727)
Resumes & cover letters (651)
Rett syndrome (28)
RNA editing (20)
RSV (84)
Schizophrenia (159)
Series A (258)
Series B (197)
Service/supplier (30)
Sickle cell disease (103)
Special edition (27)
Spinal muscular atrophy (177)
Sponsored (48)
Startups (4333)
State (2)
Stomach cancer (20)
Supply chain (113)
Tariffs (101)
The Weekly (123)
Vaccines (1151)
Venture capital (97)
Weight loss (472)
Women's health (89)
Worklife (21)
Date
Today (119)
Last 7 days (563)
Last 30 days (2592)
Last 365 days (32887)
2026 (2779)
2025 (33230)
2024 (38141)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1290)
Alabama (91)
Alaska (7)
Arizona (343)
Arkansas (14)
Asia (51575)
Australia (9060)
California (11583)
Canada (3326)
China (1175)
Colorado (491)
Connecticut (502)
Delaware (350)
Europe (118496)
Florida (1696)
Georgia (374)
Hawaii (4)
Idaho (68)
Illinois (968)
India (69)
Indiana (545)
Iowa (24)
Japan (431)
Kansas (133)
Kentucky (43)
Louisiana (29)
Maine (83)
Maryland (1461)
Massachusetts (8520)
Michigan (361)
Minnesota (667)
Mississippi (6)
Missouri (139)
Montana (35)
Nebraska (29)
Nevada (126)
New Hampshire (86)
New Jersey (3117)
New Mexico (33)
New York (3061)
North Carolina (1614)
North Dakota (10)
Northern California (5545)
Ohio (354)
Oklahoma (22)
Oregon (55)
Pennsylvania (2314)
Puerto Rico (23)
Rhode Island (50)
South America (1663)
South Carolina (65)
South Dakota (1)
Southern California (4471)
Tennessee (177)
Texas (1827)
United States (41788)
Utah (347)
Vermont (1)
Virginia (292)
Washington D.C. (88)
Washington State (976)
West Virginia (4)
Wisconsin (130)
Wyoming (2)
There are 870,468 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
February 4, 2026
·
3 min read
·
Annalee Armstrong
Press Releases
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
February 4, 2026
·
3 min read
Press Releases
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
February 4, 2026
·
4 min read
Press Releases
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Interim clinical data has exceeded the recommended guidelines of the International Bladder Cancer Group for complete response and duration of complete response
February 4, 2026
·
7 min read
Press Releases
Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement
February 4, 2026
·
4 min read
Press Releases
Bloom Burton & Co. Announces the 2026 Bloom Burton Award
Now Accepting Nomination Submissions for the Prestigious Annual Award
February 4, 2026
·
2 min read
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
SSI Diagnostica Group strengthens life science portfolio for vaccine development and quality control with acquisition of US-based multiplexing company
February 4, 2026
·
1 min read
Rare diseases
Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos
After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.
February 4, 2026
·
2 min read
·
Annalee Armstrong
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
1 of 87,047
Next
